Catalog No.
PHK60701
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human CRBN (Met1-Leu442).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Protein cereblon, CRBN, AD-006
Purification
Purified by antigen affinity column.
Accession
Q96SW2
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
A method for the detection and enrichment of endogenous cereblon substrates., PMID:40196695
The New Frontier: Merging Molecular Glue Degrader and Antibody-Drug Conjugate Modalities To Overcome Strategic Challenges., PMID:39231796
Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy., PMID:39084610
Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide., PMID:39054911
Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma., PMID:39003099
The emerging role of targeted protein degradation to treat and study cancer., PMID:38886898
Design, Synthesis, and Evaluation of BCL-2 Targeting PROTACs., PMID:38818652
Single-domain antibody-based protein degrader for synucleinopathies., PMID:38816762
Single-Domain Antibody-Based Protein Degrader for Synucleinopathies., PMID:38558982
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma., PMID:37646702
Incidence of cereblon protein in intensive care patients: a cross-sectional study., PMID:37458657
TIGIT inhibition and lenalidomide synergistically promote antimyeloma immune responses after stem cell transplantation in mice., PMID:36512425
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms., PMID:36311747
Evaluation of the Prognostic Significance of Cereblon Protein Expression in Multiple Myeloma., PMID:36125148
Drug resistance and minimal residual disease in multiple myeloma., PMID:35582527
Strategies to Reduce the On-Target Platelet Toxicity of Bcl-xL Inhibitors: PROTACs, SNIPERs and Prodrug-Based Approaches., PMID:35263486
Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma., PMID:34572892
Rational Design and Synthesis of Novel Dual PROTACs for Simultaneous Degradation of EGFR and PARP., PMID:34038131
Durvalumab Combined with Immunomodulatory Drugs (IMiD) Overcomes Suppression of Antitumor Responses due to IMiD-induced PD-L1 Upregulation on Myeloma Cells., PMID:33879556
Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma., PMID:33757580
Ablation of CRBN induces loss of type I collagen and SCH in mouse skin by fibroblast senescence via the p38 MAPK pathway., PMID:33658395
The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages., PMID:33563611
[Research Progress on the Mechanism and Clinical Data of Cereblon
in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells]., PMID:33478191
First-in-Human, Single- and Multiple-Ascending-Dose Studies in Healthy Subjects to Assess Pharmacokinetics, Pharmacodynamics, and Safety/Tolerability of Iberdomide, a Novel Cereblon E3 Ligase Modulator., PMID:32969202
A critical evaluation of the approaches to targeted protein degradation for drug discovery., PMID:31200859
Immunomodulatory drugs in the treatment of multiple myeloma., PMID:31187860
Cereblon modulator iberdomide induces degradation of the transcription factors Ikaros and Aiolos: immunomodulation in healthy volunteers and relevance to systemic lupus erythematosus., PMID:29945920
Mouse Monoclonal Antibodies Generated from Full Length Human Cereblon: Detection of Cereblon Protein in Patients with Multiple Myeloma., PMID:28926977
Aiolos Overexpression in Systemic Lupus Erythematosus B Cell Subtypes and BAFF-Induced Memory B Cell Differentiation Are Reduced by CC-220 Modulation of Cereblon Activity., PMID:28848067
Activity of lenalidomide in mantle cell lymphoma can be explained by NK cell-mediated cytotoxicity., PMID:28771673
[Drug-Resistant Mechanism of Multiple Myeloma and Its Therapy Combined with HDACi -Review]., PMID:28446321
Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma., PMID:26195701
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples., PMID:26186254
Modulation of cereblon levels by anti-myeloma agents., PMID:25860244
Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity., PMID:24206017
Screening and identification of host factors interacting with UL14 of herpes simplex virus 1., PMID:21512757
For research use only. Not for human or drug use.
